Selinexor Combination Therapy
Phase Ib/II Study of Selinexor in Combination With Carfilzomib, Subcutaneous Isatuximab Administered Via Investigational Device and Dexamethasone (SCID) for Patients With Relapsed and/or Relapsed Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 62 patients (estimated)
- Tags
- Selective Inhibiton of Nuclear Export (SINE), High Risk
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2257
- NCT Identifier
- NCT07479979
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.